Ticker > Company >

Balaxi Pharma. share price

Balaxi Pharmaceuticals Ltd.

NSE: BALAXI SECTOR: Trading  43k   144   12

64.61
-1.49 (-2.25%)
NSE: 17 Apr 4:00 PM

Price Summary

Today's High

₹ 67.19

Today's Low

₹ 63.85

52 Week High

₹ 151.45

52 Week Low

₹ 50.42

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

356.7 Cr.

Enterprise Value

326.59 Cr.

No. of Shares

5.52 Cr.

P/E

84.82

P/B

2.76

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  23.37

CASH

44.06 Cr.

DEBT

13.96 Cr.

Promoter Holding

65.99 %

EPS (TTM)

₹  0.76

Sales Growth

-35.09%

ROE

3.66 %

ROCE

6.08%

Profit Growth

-77.5 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-35.09%
3 Year-6.86%
5 Year38.86%

Profit Growth

1 Year-77.5%
3 Year-37.75%
5 Year13.18%

ROE%

1 Year3.66%
3 Year18.63%
5 Year27.87%

ROCE %

1 Year6.08%
3 Year23.81%
5 Year37.05%

Debt/Equity

0.1185

Price to Cash Flow

-194.84

Interest Cover Ratio

4.3649

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2024 65.99 0.00
Sep 2024 65.99 0.00
Jun 2024 65.99 0.00
Mar 2024 66.86 0.00
Dec 2023 71.22 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 23.8133666666667% over the past 3 years.
  • Company has a healthy liquidity position with current ratio of 4.0918.
  • The company has a high promoter holding of 65.99%.

 Limitations

  • The company has shown a poor profit growth of -37.7512431974491% for the Past 3 years.
  • The company has shown a poor revenue growth of -6.85794331929306% for the Past 3 years.
  • Company has high debtor days of 403.1031.
  • Company has negative cash flow from operations of -1.8307.
  • The company is trading at a high EV/EBITDA of 40.5318.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 12.7 15.91 19.03 21.16 11.16
Total Expenditure 12.42 15.71 17.52 19.68 11.06
Operating Profit 0.28 0.2 1.51 1.48 0.1
Other Income 1.03 0.16 0.85 1.29 2.92
Interest 0.41 0.51 0.35 0.45 0.57
Depreciation 0.13 0.12 0.12 0.12 0.11
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.77 -0.26 1.89 2.2 2.33
Tax 0.28 0.31 0.51 0.54 0.59
Profit After Tax 0.49 -0.58 1.38 1.66 1.74
Adjusted EPS (Rs) 0.1 -0.11 0.25 0.3 0.32

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 45.63 86.87 101.29 108.14 70.2
Total Expenditure 36.99 67.85 83.99 91.27 64.84
Operating Profit 8.65 19.02 17.3 16.87 5.35
Other Income 0.59 1.81 2.75 6.6 2.4
Interest 0.05 0.15 0.1 0.51 1.66
Depreciation 0.01 0.09 0.25 0.52 0.51
Exceptional Items 0 0 0 0 0
Profit Before Tax 9.19 20.6 19.7 22.45 5.58
Tax 2.69 5.46 5.03 6.23 1.93
Net Profit 6.5 15.13 14.67 16.22 3.65
Adjusted EPS (Rs.) 1.3 3.03 2.93 3.19 0.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 10 10 10 10.18 10.9
Total Reserves 18.11 33.25 47.91 81.93 110.65
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0.01 0.04 2.79 2.78
Current liabilities 9.79 25.67 23.97 34.83 30.04
Total Liabilities 37.91 68.92 81.92 129.72 154.36
Assets
Net Block 0.19 0.69 2.2 7.89 7.1
Capital WIP 0 0 0.57 2.83 2.31
Intangible WIP 0 0 0 0 0
Investments 0.1 19.54 19.61 19.54 19.88
Loans & Advances 0.92 0.02 0.59 0.04 1.78
Other N/C Assets 0 0 4.87 0.4 0.4
Current Assets 36.7 48.67 54.08 99.02 122.9
Total Assets 37.91 68.92 81.92 129.72 154.36
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 9.19 20.6 19.7 22.45 5.58
Adjustment 0.01 0.1 0.31 0.97 2.05
Changes in Assets & Liabilities -22.82 -4.8 -5.44 -25.08 -4.39
Tax Paid -0.74 -2.44 -5.69 -5.41 -5.08
Operating Cash Flow -14.37 13.46 8.89 -7.07 -1.83
Investing Cash Flow -0.28 -20.03 -6.87 -2.29 0.46
Financing Cash Flow 18.1 3.49 -1.64 26.39 27.55
Net Cash Flow 3.44 -3.08 0.38 17.03 26.19

Corporate Actions

Investors Details

PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
promoters 71.22 66.86 65.99 65.99 65.99
ashish maheshwari 1.77 1.66 1.64 1.64 1.64
balaxi overseas private l... 68.42 64.23 63.40 63.40 63.40
minoshi maheshwari 1.03 0.97 0.96 0.96 0.96
PARTICULARS Dec 2023% Mar 2024% Jun 2024% Sep 2024% Dec 2024%
investors 28.78 33.14 34.01 34.01 34.01
amol anand mantri 1.70 1.59 - 1.41 1.41
elara india opportunities... 9.29 8.72 8.50 8.29 8.29
investor education and pr... - 0.71 - 0.70 0.70
kunal mahendra bhakta - - 1.86 1.86 1.86
mgc fund limited 9.29 8.49 8.38 8.19 8.19
p p zibi jose 1.13 1.10 1.09 1.10 1.12
rajasthan global securiti... - 2.93 2.89 2.89 1.66
investor education and pr... 0.76 - 0.70 - -
mr. kunal bhakta - 1.43 - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Balaxi Pharma. - Quaterly Results 10 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 10 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 10 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharmaceuticals’ arm incorporates new wholly owned subsidiary 14 Feb, 5:40 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 3 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 3 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 3 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 29 May, 12:00 PM Balaxi Pharma. - Quaterly Results 1 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 1 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 1 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 23 May, 12:00 PM Balaxi Pharma. - Quaterly Results 23 May, 12:00 PM Balaxi Pharma. - Quaterly Results 23 May, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharmaceuticals’ arm completes acquisition of 99% stake in BHES 8 Nov, 4:26 PM Balaxi Pharmaceuticals to expand portfolio of proprietary, niche branded formulations 28 Oct, 11:50 AM Balaxi Pharmaceuticals’ arm acquires 100% stake in Balaxi Healthcare Honduras 12 May, 9:17 AM Balaxi Pharmaceuticals' arm incorporates wholly owned subsidiary 24 Apr, 10:05 AM Balaxi Ventures’ arm acquires BHD, BHG 10 Jun, 2:50 PM

Balaxi Pharma. Stock Price Analysis and Quick Research Report. Is Balaxi Pharma. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Balaxi Pharma. stock price today is Rs 64.61. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Balaxi Pharma. . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Balaxi Pharma. has a PE ratio of 84.8234212944729 which is high and comparatively overvalued .

  • Share Price: - The current share price of Balaxi Pharma. is Rs 64.61. One can use valuation calculators of ticker to know if Balaxi Pharma. share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Balaxi Pharma. has ROA of 2.5698 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Balaxi Pharma. has a Current ratio of 4.0918 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Balaxi Pharma. has a ROE of 3.6579 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Balaxi Pharma. has a Debt to Equity ratio of 0.1185 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Balaxi Pharma. has reported revenue growth of -35.0865 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Balaxi Pharma. for the current financial year is 7.62764260071798 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Balaxi Pharma. is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Balaxi Pharma. is Rs 0.7617 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Balaxi Pharma. in Ticker for free. Also, one can get the intrinsic value of Balaxi Pharma. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Balaxi Pharma.
X